Home/Filings/4/0000899243-24-000153
4//SEC Filing

CVF, LLC 4

Accession 0000899243-24-000153

CIK 0001572616other

Filed

Feb 5, 7:00 PM ET

Accepted

Feb 6, 8:39 PM ET

Size

21.5 KB

Accession

0000899243-24-000153

Insider Transaction Report

Form 4
Period: 2024-02-06
CVF, LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    2024-02-06+3,419,8763,419,876 total
  • Conversion

    Series F Preferred Stock

    2024-02-06333,9570 total
    Common Stock
  • Conversion

    Series D Preferred Stock

    2024-02-064,090,8720 total
    Common Stock
  • Conversion

    Convertible Promissory Note

    2024-02-0600 total
    Exp: 2024-12-31Common Stock
  • Conversion

    Common Stock

    2024-02-06+920,6614,340,537 total
  • Conversion

    Series E Preferred Stock

    2024-02-062,914,2280 total
    Common Stock
  • Purchase

    Common Stock

    2024-02-06$15.00/sh+333,333$4,999,9954,673,870 total
Transactions
  • Conversion

    Common Stock

    2024-02-06+3,419,8763,419,876 total
  • Conversion

    Series D Preferred Stock

    2024-02-064,090,8720 total
    Common Stock
  • Conversion

    Series E Preferred Stock

    2024-02-062,914,2280 total
    Common Stock
  • Conversion

    Series F Preferred Stock

    2024-02-06333,9570 total
    Common Stock
  • Purchase

    Common Stock

    2024-02-06$15.00/sh+333,333$4,999,9954,673,870 total
  • Conversion

    Convertible Promissory Note

    2024-02-0600 total
    Exp: 2024-12-31Common Stock
  • Conversion

    Common Stock

    2024-02-06+920,6614,340,537 total
Footnotes (4)
  • [F1]Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's option, on a 1-1 basis, with such ratio being subject to adjustment from time to time for customary events affecting the preferred stock and common stock, and has no expiration date. On January 26, 2024, the Issuer's board approved a 1-for-2.146 reverse stock split of its issued and outstanding shares of common stock, as a result of which the conversion ratio for the Issuer's preferred stock was correspondingly adjusted to 1 share of common stock issuable for 2.146 shares of the preferred stock. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering on February 6, 2024 at such ratio.
  • [F2]The Convertible Note automatically converts into shares of the Issuer's common stock upon the occurrence of certain additional issuances of the Issuer's capital stock, including in connection with an initial public offering of the Issuer's common stock with gross proceeds of at least $80,000,000 or a resulting market capitalization of the Issuer's common stock equal to at least $1,000,000,000. In the event of such an initial public offering, all of the outstanding principal and interest under the convertible note will automatically convert into shares of the Issuer's common stock at a price equal to the lessor of (a) 80% of the per share offering price of common stock in the initial public offering; and (b) the price per share that results when $770,000,000 is divided by the total number of shares of the Issuer's common stock then outstanding, calculated on a fully diluted basis.
  • [F3](Continued from Footnote 2) Upon the closing of the Issuer's initial public offering on February 6, 2024 meeting the foregoing criteria, the aggregate principal amount of the Convertible Note of approximately $10.9 million, including accrued interest, automatically converted into 920,661 shares of the Issuer's common stock.
  • [F4]HCC Manager LLC, manager of CVF, LLC, exercises voting and investment power with respect to shares held by CVF, LLC. HCC Manager LLC disclaims beneficial ownership of all shares held by CVF, LLC, except to the extent of its pecuniary interest therein.

Issuer

Fractyl Health, Inc.

CIK 0001572616

Entity typeother

Related Parties

1
  • filerCIK 0001112278

Filing Metadata

Form type
4
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 8:39 PM ET
Size
21.5 KB